Alimta

... Kalypsys Announces Key Appointments Kalypsys Announces Key Appointments -Additions Made to Board of Directors- SAN DIEGO, March 15 /PRNewswire/ - Kalypsys, a privately owned San Diego-based drug discovery and development company, announced today the appointment of Philip Needleman, PhD and August Watanabe, MD to its Board of Directors.

Dr.

Needleman brings more than 30 years of pharmaceutical experience to the Board, most recently having served as senior executive vice president of Pharmacia.

While there, he also held positions as chief scientist and chairman of research and development, overseeing the commercialization of blockbuster drugs including Celebrex(R), Bextra(R), Dynastat(R) and Inspra(R).

Prior to his work at Pharmacia, Dr.

Needleman served as president of Searle Research and Development and senior vice president and chief scientist of Monsanto.

He spent 25 years as professor and chairman of the department of pharmacology at Washington University School of Medicine and has been honored with the John Jacob Abel Award of the American Pharmacology Society, the Research Achievement Award of the American Heart Association and the Chester Stock Award of the Memorial Sloane Kettering Cancer Center.

Dr.

Needleman is a member of both the National Academy of Science and the Institute of Medicine.

Also joining the Kalypsys Board of Directors is Dr.

August Watanabe, a former senior executive at Eli Lilly Company where he served for 13 years during which...

Read more...